Tivozanib hydrochloride hydrate 是一种有效的、选择性的、具有口服活性的VEGFR 酪氨酸激酶抑制剂，对 VEGFR-1、VEGFR-2、VEGFR-3的IC50值分别为 0.21、0.16、0.24 nM。Tivozanib hydrochloride hydrate 抑制肿瘤组织中的血管生成和血管通透性，并显示出抗肿瘤活性。Tivozanib hydrochloride hydrate 具有研究转移性肾细胞癌 (RCC) 的潜力。

Tivozanib hydrochloride hydrate is a potent and selective and orally active VEGFR tyrosine kinase inhibitor with IC 50 是of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC) [1] [2] [3].

Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3 [2].

Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7% [4].

682745-41-1

C22H22Cl2N4O6

509.34

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years